Antibody ID	ANTI0TPUPS
Antibody Name	#84.7
Organization	Eisai Co., Ltd.; NHO Osaka National Hospital.
Synonyms	#84.7    Click to Show/Hide
Antibody Type	Monoclonal antibody (mAb)
Antigen Name	Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6)					Antigen Info
Click to Show/Hide the Sequence Information of This Antibody

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 0.015 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 0.015 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 0.015 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 0.015 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.023 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.027 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.029 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.031 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.032 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.034 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.035 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.035 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.035 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.035 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.036 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.037 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.038 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.038 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.038 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.038 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.039 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.039 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.039 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.039 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.04 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.041 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.043 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.043 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.043 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.044 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.047 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.047 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.051 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.052 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.057 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.057 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.061 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.07 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.072 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.074 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.075 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.075 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.076 nM	Positive CEACAM6 expression (CEACAM6 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.076 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.083 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.6 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Ref 1	Antibody-drug complexes